Kyverna Therapeutics, Inc. (KYTX)
Largest Insider Buys in Sector
KYTX Stock Price History Chart
KYTX Stock Performance
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical …
Insider Activity of Kyverna Therapeutics, Inc.
Over the last 12 months, insiders at Kyverna Therapeutics, Inc. have bought $20.02M and sold $0 worth of Kyverna Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Kyverna Therapeutics, Inc. have bought $20.02M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $100.1M.
The last purchase of 910,000 shares for transaction amount of $20.02M was made by GILEAD SCIENCES, INC. (10 percent owner) on 2024‑02‑12.
List of Insider Buy and Sell Transactions, Kyverna Therapeutics, Inc.
| 2024-02-12 | 10 percent owner | 910,000 8.0369% | $22.00 | $20.02M | -73.10% |